Peer Review, People, Startups

Why did Liz Barrett turn her back on a top job at Novartis in exchange for the helm of a biotech you never heard of?

Liz Barrett wasn’t looking for a job in biotech when she got the call from a corporate headhunter she knew well. The timing was terrible — just into a new job as head of Novartis’ global, $14 billion oncology group under a new CEO looking to push a longterm change in culture.

That’s a big deal. And she had moved over from the head role at Pfizer oncology, another Big Pharma with a major mission in oncology.

There was also one other problem: She didn't know the company. What was UroGen Pharma about? And while she knew of executive chairman Arie Belldegrun, who led Kite to a $12 billion buyout, she had never met him before.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 44,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->